178 filings
Page 2 of 9
8-K/A
bzfznolh 88c
28 Oct 22
Other Events
4:05pm
8-K
0vi4m
26 Oct 22
Aravive Announces Approximately $41.5 Million Private Placement Financing
4:35pm
8-K
wpouws9xpsz726g2
11 Oct 22
Aravive Receives Third Development Milestone from 3D Medicines
7:05am
8-K
svc 536psi2ce20gpwub
27 Sep 22
Regulation FD Disclosure
7:05am
8-K
vd56jd
22 Sep 22
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
ik9iwof84 5wf
26 Aug 22
Regulation FD Disclosure
4:06pm
8-K
l4u99vs
26 Aug 22
Regulation FD Disclosure
7:05am
8-K
exr8d qzrvn1pry
11 Aug 22
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
7:15am
8-K
lak4dlm3vs0vqocyqe2l
11 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:05am
8-K
cl8ph1b4bvfj 3isp7e3
5 Jul 22
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
7:05am
8-K
09ivea1 0m65wcjlr8j
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
8-K
09z4c 6frq8epx
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
frb i15huzr2yxqn
12 May 22
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
7:05am
8-K
m45ldvojmmh3 6i
11 May 22
Regulation FD Disclosure
7:01am
8-K
t8kyt1lkxo32kn
4 Apr 22
Submission of Matters to a Vote of Security Holders
4:16pm
8-K
4kk2b0lss 9sk
1 Apr 22
Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
7:05am
8-K
wtjws9ibg2tcojj g10
31 Mar 22
Aravive Reports Fourth Quarter and Full Year 2021
4:05pm
8-K
2vmhpitvdx1m9 5d9jxh
31 Mar 22
Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:26am
8-K
l5vug o62z
25 Mar 22
Departure of Directors or Certain Officers
4:07pm
8-K
w5b7u0anuwuercjg8
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm